The prevailing Biosimulation Market Economic Outlook is largely decoupled from general economic cycles, as its value proposition—cost reduction in drug development—becomes even more compelling during periods of fiscal restraint. However, the market is highly sensitive to the R&D budget volatility of pharmaceutical and biotechnology companies. A strong economic outlook...